Human Rabies Vaccine Market: By Vaccine Type, By Route of Administration, By Product Type, By Application, Post-exposure Prophylaxis ) and Geography

Human Rabies Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Vaccine Type (Killed Rabies Vaccines, Rabies Immunoglobulins, Rabies Monoclonal Antibodies), By Route of Administration (Intra Muscular, Intra Dermal), By Product Type (Chicken Embryo Cell Vaccines, Vero Cells, Human Diploid Cell Vaccines), By Application (Pre-exposure Prophylaxis(Pr-EP), Post-exposure Prophylaxis (PEP)) and Region

Human Rabies Vaccine Market size was valued at US$ 1,343.6 million in 2023 and is estimated to grow at 4.9% CAGR from 2024 to 2030. Human Rabies vaccine is the class of vaccines that gives protection from a zoonotic disease called rabies mainly spread by dogs. There are three types of vaccines specifically chicken embryo cell vaccines (CCEEV), Vero cells, and Human diploid cell vaccines. The market of Human Rabies Vaccine includes killed rabies vaccines, rabies immunoglobulins, and monoclonal antibodies and recent trends are of DNA and mRNA vaccines. The key drivers of the Human Rabies Vaccine are the urbanization of stray dogs, government and various healthcare organizations initiatives, increased pet ownership, and increasing awareness about vaccines.

The opportunities for the companies for the market are the increased awareness and vaccination initiatives of certain organizations such National Rabies Control Program (NRCP) from the Indian government, the Thailand Red Cross (TRC), etc. The key trends in the market are the increasing occurrence of rabies, and presence of key players in vaccine manufacturing, and the availability of vaccines in rural areas. As per WHO, the suggestion of switching to ID (Intra-Dermal) form IM (Intra-Muscular) based administration will help reduce the Human Rabies Vaccine usage from the current scenario of 60M vials to 20M vials per year globally (driven by China). This happens because the dosage regime is significantly reduced from 0.5 - 1 ml to 0.1 ml from IM to ID respectively. The market is also affected by the WHO program of increasing oral vaccination of wild and tame animals. Despite the decrease in vaccine usage, because of the “ZERO by 30” program from WHO the global market is expected to expand. The major producers and end users of the Human Rabies Vaccine in the global market are China and India.

Rabies is a deadly viral disease transmitted primarily through animal bites. Human rabies vaccines play a crucial role in preventing rabies infection and saving lives. Travel advisories and educational programs targeted towards travelers visiting rabies-endemic regions create a growing market for PrEP vaccines to ensure travelers are adequately protected. Also, community outreach programs in high-risk areas educate people about rabies prevention measures, including responsible pet ownership and the importance of post-exposure prophylaxis (PEP) after animal bites. This awareness fuels demand for PEP vaccines. Moreover, the "Zero by 30" initiative spearheaded by the World Health Organization (WHO) aims to eliminate dog-mediated human rabies deaths by 2030. This global focus translates to increased funding and support for rabies control programs, leading to a rise in vaccine demand. Many countries are implementing mass vaccination campaigns for dogs, the primary reservoir of rabies.

This indirect strategy reduces the risk of rabies transmission to humans and creates a smaller, long-term demand for PEP vaccines. Also, investments in healthcare infrastructure, particularly in developing regions, improve access to rabies vaccines and post-exposure treatment, driving market growth. A growing global middle class with increased disposable income is leading to more people traveling internationally, often to areas with higher rabies prevalence. This necessitates PrEP for travelers, boosting market demand. Increased global trade and movement of animals can inadvertently introduce rabies strains into new regions. This underscores the importance of rabies control programs and vaccination efforts. Additionally, the growing trend towards responsible pet ownership and animal welfare initiatives can lead to increased pet vaccinations, indirectly impacting the human rabies vaccines market by reducing the risk of rabies transmission from animals to humans. However, uneven access to healthcare facilities and robust cold chain infrastructure in some regions can hinder vaccine distribution and administration.

Human Rabies Vaccine Market Key Developments:

  • In April 2024. Sanofi has announced the launch of Verorab® (Sanofi Inactivated Rabies Vaccine) in the UK, an inactivated rabies vaccine indicated for pre-exposure and post-exposure rabies prophylaxis in all age groups.
  • In July 2024, Gavi, the Vaccine Alliance, in collaboration with partners, is announcing support for human rabies vaccines for post-exposure prophylaxis (PEP) as part of routine immunization. Eligible countries are receiving guidance on how to access these vaccines under Gavi's cofinancing policy. The first round of applications will be accepted by mid-July 2024
  • In December 2022, Everest Medicines launched a novel mRNA Rabies Vaccine development and the completion of a preclinical proof-of-concept study. This is a association with Providence Therapeutics that concentrates on a new rabies vaccine candidate.
  • In April 2022, Cadila Pharmaceuticals released a three-dose recombinant nanoparticle-based G protein rabies vaccine in Ahmedabad. This regimen is to be given over one week (on day 0, day three, and day seven) after exposure to the virus. It is the first in a long list of existing rabies vaccines that require five doses.

Human Rabies Vaccine Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.9%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Human Rabies Vaccine Market Dynamics

The growing population and increased awareness in countries such as India, China, and Africa are projected to drive the market growth of Human Rabies Vaccine. The Indian population is growing at a steady pace contributing around 36 % to the total world rabies deaths. This happens because of the high number of stray dogs. Recently, several new improvements such as M-ab, DNA, MRNA-based drugs, and so on have been achieved. The pricing of the Human Rabies Vaccine has been drastically reduced for example: in 2015, it cost around 1200 dollars for a post-exposure Rabies shot but now it has been reduced to around 280 dollars. Because of the increasing population as well as increased exposure to the infected animals with the program of “ ZERO by 30” and several other organizations promoting Rabies vaccines the global Human Rabies vaccine market is likely to expand. Furthermore, many recent improvements and new drug candidates have been identified which indicates there is ongoing research.

Research and development efforts are exploring new rabies vaccine technologies with potential benefits. These include more affordable vaccines, vaccines with longer shelf life requiring less stringent cold chain storage, and single-dose vaccination regimens. In addition, continuations improvements in vaccine safety profiles and efficacy can encourage wider adoption and increase confidence in rabies vaccines, leading to greater market acceptance. Moreover, developing thermostable vaccines that can withstand higher temperatures during storage and transportation is crucial for regions with limited cold chain infrastructure, expanding vaccine accessibility. Furthermore, media coverage of rabies outbreaks and public health campaigns emphasizing the dangers of rabies and the importance of vaccination are raising awareness among the public. This translates to increased demand for both PrEP and PEP vaccines.

Human Rabies Vaccine Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 1,343.6 million

Market CAGR

4.9%

By Vaccine Type

  • Killed Rabies Vaccines
  • Rabies Immunoglobulins
  • Rabies Monoclonal Antibodies

By Administration

  • Intramuscular
  • Intra Dermal

By Product Type

  • Chicken Embryo Cell Vaccines
  • Vero Cells
  • Human Diploid Cell Vaccines

By End User

  • Pre-exposure Prophylaxis(Pr-EP)
  • Post-exposure Prophylaxis (PEP)

Key Features of the Report

  • The human rabies vaccine market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.

Download Free Sample Report

Frequently Asked Questions

The human rabies vaccine market size was valued at US$ 1,343.6 million in 2023 and is estimated to grow at 4.9% CAGR from 2024 to 2030

M-ab, DNA, mRNA-based drugs are the important technological advancements as these dictate the future market.

The opportunities for the companies for Human Rabies Vaccine Market are the increased awareness and vaccination initiatives of certain organizations such National Rabies Control Program (NRCP) from Indian government, Thailand Red Cross (TRC), etc.

The key drivers of the human rabies vaccine are the urbanization of stray dogs, government and world organizations initiatives, increased pet ownership, increasing awareness about vaccines.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Human Rabies Vaccine Market Introduction 
2.1.Global Human Rabies Vaccine Market  - Taxonomy
2.2.Global Human Rabies Vaccine Market  - Definitions
2.2.1.Vaccine Type
2.2.2.Administration
2.2.3.Product
2.2.4.End User
2.2.5.Region
3.Global Human Rabies Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Human Rabies Vaccine Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Human Rabies Vaccine Market  By Vaccine Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Killed Rabies Vaccines
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Rabies Immunoglobulins
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Rabies Monoclonal Antibodies
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6.Global Human Rabies Vaccine Market  By Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Intramuscular
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Intra Dermal
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Human Rabies Vaccine Market  By Product, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Chicken Embryo Cell Vaccines
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Vero Cells
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Human Diploid Cell Vaccines
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Human Rabies Vaccine Market  By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Pre-exposure Prophylaxis(Pr-EP)
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Post-exposure Prophylaxis (PEP)
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
9.Global Human Rabies Vaccine Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Human Rabies Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Killed Rabies Vaccines
10.1.2.Rabies Immunoglobulins
10.1.3.Rabies Monoclonal Antibodies
10.2.  Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Intramuscular
10.2.2.Intra Dermal
10.3.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Chicken Embryo Cell Vaccines
10.3.2.Vero Cells
10.3.3.Human Diploid Cell Vaccines
10.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Pre-exposure Prophylaxis(Pr-EP)
10.4.2.Post-exposure Prophylaxis (PEP)
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Human Rabies Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Vaccine Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Killed Rabies Vaccines
11.1.2.Rabies Immunoglobulins
11.1.3.Rabies Monoclonal Antibodies
11.2.  Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Intramuscular
11.2.2.Intra Dermal
11.3.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Chicken Embryo Cell Vaccines
11.3.2.Vero Cells
11.3.3.Human Diploid Cell Vaccines
11.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Pre-exposure Prophylaxis(Pr-EP)
11.4.2.Post-exposure Prophylaxis (PEP)
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Human Rabies Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Vaccine Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Killed Rabies Vaccines
12.1.2.Rabies Immunoglobulins
12.1.3.Rabies Monoclonal Antibodies
12.2.  Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Intramuscular
12.2.2.Intra Dermal
12.3.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Chicken Embryo Cell Vaccines
12.3.2.Vero Cells
12.3.3.Human Diploid Cell Vaccines
12.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Pre-exposure Prophylaxis(Pr-EP)
12.4.2.Post-exposure Prophylaxis (PEP)
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Human Rabies Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Vaccine Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Killed Rabies Vaccines
13.1.2.Rabies Immunoglobulins
13.1.3.Rabies Monoclonal Antibodies
13.2.  Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Intramuscular
13.2.2.Intra Dermal
13.3.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Chicken Embryo Cell Vaccines
13.3.2.Vero Cells
13.3.3.Human Diploid Cell Vaccines
13.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Pre-exposure Prophylaxis(Pr-EP)
13.4.2.Post-exposure Prophylaxis (PEP)
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Human Rabies Vaccine Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Vaccine Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Killed Rabies Vaccines
14.1.2.Rabies Immunoglobulins
14.1.3.Rabies Monoclonal Antibodies
14.2.  Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Intramuscular
14.2.2.Intra Dermal
14.3.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Chicken Embryo Cell Vaccines
14.3.2.Vero Cells
14.3.3.Human Diploid Cell Vaccines
14.4.  End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Pre-exposure Prophylaxis(Pr-EP)
14.4.2.Post-exposure Prophylaxis (PEP)
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.AstraZeneca
15.2.2.Berna Biotech
15.2.3.Bharat Biotech
15.2.4.Cadila
15.2.5.Chengda Pharmaceuticals
15.2.6.GlaxoSmithKline
15.2.7.Indian Immunologicals
15.2.8.Medimmune
15.2.9.Merck
15.2.10.Novartis
15.2.11.Pfizer
15.2.12.Sanofi
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  • AstraZeneca
  • Berna Biotech
  • Bharat Biotech
  • Cadila
  • Chengda Pharmaceuticals
  • GlaxoSmithKline
  • Indian Immunologicals
  • Medimmune
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • Serum Institute of India
  • Zydus

Related Industry Reports